Exagen
XGN
33 hedge funds and large institutions have $11.4M invested in Exagen in 2024 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 10 increasing their positions, 12 reducing their positions, and closing their positions.
16% more capital invested
Capital invested by funds: $9.87M → $11.4M (+$1.57M)
6% more funds holding
Funds holding: 31 → 33 (+2)
0.2% more ownership
Funds ownership: 35.99% → 36.19% (+0.2%)
17% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
+$130K |
| 2 |
PWM
Palumbo Wealth Management
Great Neck,
New York
|
+$82K |
| 3 |
Renaissance Technologies
New York
|
+$77K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$30.7K |
| 5 |
RI
RTW Investments
New York
|
+$12.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$43.9K |
| 2 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$41.7K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$32.2K |
| 4 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$25.4K |
| 5 |
BlackRock
New York
|
-$20.2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TRCT
26
Tower Research Capital (TRC)
New York
| $11.5K | +$3.89K | +2,297 | +57% |
|
27
Bank of America
Charlotte,
North Carolina
| $11.1K | +$124 | +73 | +1% |
|
28
Barclays
London,
United Kingdom
| $9.36K | – | – | – |
|
29
Wells Fargo
San Francisco,
California
| $4.34K | -$119 | -70 | -3% |
|
30
Simplex Trading
Chicago,
Illinois
| $1K | +$1.07K | +634 | New |
|
31
Qube Research & Technologies (QRT)
London,
United Kingdom
| $372 | – | – | – |
|
32
JP Morgan Chase
New York
| $64 | +$2 | +1 | +3% |
|
33
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$252 | +149 | +169% |
|
XGN Hedge Fund Activity: Q2 2024 in Review
33 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Exagen (XGN) for Q2 2024, worth a combined $11.4M — up 16% from $9.87M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new XGN positions and 0 closed out — a net gain of 2 holders — while 10 added to existing stakes and 12 trimmed.
The largest buyer was Kennedy Capital Management, opening a new position worth an estimated $130K. The largest seller was Stonepine Capital Management, cutting an estimated $43.9K.
- 33 institutional investors held Exagen (XGN) as of Q2 2024, up from 31 in Q1 2024.
- Funds reported $11.4M of Exagen stock for Q2 2024, up 16% quarter-over-quarter.
- 2 funds opened new Exagen positions in Q2 2024 and 0 closed out, a net change of +2 holders.
- The largest Exagen buyer in Q2 2024 was Kennedy Capital Management, an estimated $130K added.
- The largest Exagen seller in Q2 2024 was Stonepine Capital Management, an estimated $43.9K sold.
Based on aggregated 13F filings for Q2 2024.